Drugs / PR1 leukemia peptide vaccine
PR1 leukemia peptide vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004918 | Dec 1999 → Dec 2007 | acute myeloid leukemia, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome with excess blasts, refractory anemia with excess blasts in transformation | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00454168 | May 2005 → Apr 2009 | leukemia | The Vaccine Company | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR1 leukemia peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454168 ↗ |
| Known as | Pr1 vac | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297811 ↗ |
| Known as | Proteinase 3 pr1 peptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297811 ↗ |
| Modality | Vaccine | “PR1 leukemia peptide vaccine” NCT00004918 ↗ |
| Route | Subcutaneous | “Given subcutaneously” NCT00454168 ↗ |